The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
Andrea K MiyahiraHoward R SoulePublished in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
Prostate-Specific Membrane Antigen (PSMA) is a credentialed imaging and therapy (theranostic) target for the detection and treatment of prostate cancer. PSMA-targeted positron emission tomography (PET) imaging and molecular radiotherapy (MRT) are promising evolving technologies that will improve the outcomes of prostate cancer patients. In anticipation of this new era in prostate cancer theranostics, this article will review the history of PSMA from discovery, through early and late stage clinical trials. Since 1993, the Prostate Cancer Foundation (PCF) has funded critical and foundational PSMA research that established this theranostic revolution. The history and role of PCF funding in this field will be discussed.
Keyphrases
- prostate cancer
- pet imaging
- positron emission tomography
- pet ct
- radical prostatectomy
- computed tomography
- clinical trial
- photodynamic therapy
- fluorescence imaging
- radiation therapy
- stem cells
- small molecule
- early stage
- squamous cell carcinoma
- bone marrow
- weight loss
- smoking cessation
- phase ii
- mesenchymal stem cells
- study protocol
- locally advanced
- replacement therapy
- placebo controlled